All In Biotech

Drug Trial Radar · NCT03863015

IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Mar 4, 2019

Primary completion

Dec 23, 2019

Study completion Jun 30, 2020

Sponsor

Lead sponsor
Christian HassagerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Resuscitated cardiac arrest is associated with a systemic inflammatory response that is directly associated with poor prognosis. Inhibition of the IL-6 mediated immune response may potentially inhibit the systemic inflammatory response, potentially improving the prognosis of these severely ill patients.

Conditions

  • Heart Arrest
  • Out-Of-Hospital Cardiac Arrest
  • Systemic Inflammatory Response Syndrome

Interventions

  • Tocilizumab 20 Mg/mL Intravenous SolutionDrug

    Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion

  • isotonic salineDrug

    A one hour infusion of 100mL isotonic saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of hsCRPTime frame: Daily measurements from admission to 72 hours after admission.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.